Breaking News Instant updates and real-time market news.

ALNY

Alnylam

$75.04

-0.96 (-1.26%)

, SNY

Sanofi

$49.10

0.46 (0.95%)

07:02
09/20/17
09/20
07:02
09/20/17
07:02

Alnylam, Sanofi say APOLLO Phase 3 study met primary, secondary endpoints

Alnylam Pharmaceuticals (ALNY) and Sanofi Genzyme, the specialty care global business unit of Sanofi (SNY), announced that the APOLLO Phase 3 study of patisiran, an investigational RNAi therapeutic being developed for patients with hereditary ATTR amyloidosis with polyneuropathy, met its primary efficacy endpoint and all secondary endpoints. The primary endpoint for the study was the change from baseline in the modified neuropathy impairment score at 18 months. The key secondary endpoint was improvement in quality of life assessed by the Norfolk Quality of Life Questionnaire-Diabetic Neuropathy. The APOLLO trial enrolled 225 hATTR amyloidosis patients with polyneuropathy, representing 39 genotypes, at 44 study sites in 19 countries around the world. Patients were randomized 2:1 to patisiran or placebo, with patisiran administered intravenously at 0.3 mg/kg once every three weeks for 18 months. For both the mNIS+7 and Norfolk QOL-DN endpoint measures, a lower score indicates a better clinical result. At 18 months, the mean change from baseline in mNIS+7 was significantly lower in the patisiran group as compared with placebo. Patients in the patisiran group experienced improvement in quality of life compared to placebo, as assessed by the Norfolk Quality of Life Questionnaire-Diabetic Neuropathy. The mean and median changes in QOL scores for patisiran also both achieved negative values, indicating an improvement overall and in the majority of patients compared with baseline. All 5 other secondary endpoints also demonstrated statistically significant favorable differences in the patisiran arm compared to placebo. Based on these positive results, Alnylam expects to file its first New Drug Application in late 2017 and first Marketing Authorisation Application shortly thereafter. Sanofi Genzyme is currently preparing for regulatory filings for patisiran in Japan, Brazil and other countries, to begin in the first half of 2018. Pending regulatory approvals, Alnylam will commercialize patisiran in the U.S., Canada and Western Europe, with Sanofi Genzyme commercializing the product in the rest of the world.

ALNY

Alnylam

$75.04

-0.96 (-1.26%)

SNY

Sanofi

$49.10

0.46 (0.95%)

  • 18

    Oct

ALNY Alnylam
$75.04

-0.96 (-1.26%)

09/18/17
JEFF
09/18/17
NO CHANGE
Target $102
JEFF
Buy
Jefferies says buy Alnylam ahead of Apollo data readout
Topline results for Alnylam Pharma's Apollo trial are expected in the next two weeks, which, if positive, can drive 15%-20% upside in the shares, Jefferies analyst Maury Raycroft tells investors in a research note. After speaking to a hereditary ATTR amyloidosis doctor, Raycroft says he would buy shares of Alnylam ahead of the data readout. He has a Buy rating on the shares with a $102 price target.
09/15/17
NOMU
09/15/17
INITIATION
Target $56
NOMU
Reduce
Nomura says reduce Alnylam exposure, starts with Reduce rating
Nomura Instinet analyst Christopher Marai last night initiated Alnylam Pharmaceuticals with a Reduce rating and $56 price target. The analyst recommends reducing exposure to the shares ahead of the patisiran Phase 3 Apollo readout. He sees a good chance of a successful readout, but notes that a "possible, unlikely disappointment" could send shares "substantially" lower. A patisiran launch will likely be "slow and disappointing," based on competition and the relatively poor product profile, Marai told investors in a research note.
09/14/17
NOMU
09/14/17
INITIATION
Target $56
NOMU
Reduce
Alnylam initiated with a Reduce at Nomura Instinet
Nomura initiated Alnylam with a Reduce and a $56 price target.
09/08/17
LEER
09/08/17
NO CHANGE
Target $72
LEER
Market Perform
Alnylam price target lowered to $72 from $83 at Leerink
Leerink analyst Paul Matteis lowered his price target for Alnylam Pharmaceuticals to $72 after removing sales from non-inhibitor patients from his valuation and reducing his odds-of-success for fitusiran in the inhibitor population to 35%. The changes follow Alnylam's announcement that dosing in the Phase 3 Atlas programs has been halted due to a fatal thrombotic event in a patient with hemophilia A without inhibitors. The analyst keeps a Market Perform rating on Alnylam.
SNY Sanofi
$49.10

0.46 (0.95%)

09/11/17
FBCO
09/11/17
NO CHANGE
Target $485
FBCO
Outperform
Regeneron, Sanofi asthma trial 'statistically significant,' says Credit Suisse
Credit Suisse analyst Alethia Young notes that Regeneron (REGN)/Sanofi (SNY) released top-line asthma results, and the overall trial was "statistically significant." Specifically, the trial hit in the overall population, but it is unclear if the trial was statistically significant in the low eosinophil level patients alone, she notes. The analyst reiterates an Outperform rating and $485 price target on Regeneron's shares.
08/30/17
08/30/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Sanofi (SNY) upgraded to Hold from Reduce at HSBC, with analyst Steve McGarry citing valuation. 2. M.D.C. Holdings (MDC) upgraded to Market Perform from Underperform at Wells Fargo with analyst Stephen East saying he sees "little reason the equity would move meaningfully lower" from current levels. 3. Ciena (CIEN) upgraded to Buy from Neutral at Citi with analyst Stanley Kovler saying the risk/reward is positive into third quarter results. 4. Six Flags (SIX) upgraded to Buy from Neutral at Hilliard Lyons with analyst Jeff Thomison citing improved valuation based on its 13% year-to-date pullback. 5. Prospect Capital (PSEC) upgraded to Market Perform from Underperform at Raymond James with analyst Robert Dodd saying he expects near-term earnings will cover the lower dividend run-rate but notes downside risk remains. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/30/17
HSBC
08/30/17
UPGRADE
Target $81
HSBC
Hold
Sanofi upgraded to Hold from Reduce at HSBC
HSBC analyst Steve McGarry upgraded Sanofi to Hold and increased its price target to $81 from $79 citing valuation and said he sees few catalysts to own the shares either.
07/31/17
ADAM
07/31/17
NO CHANGE
Target $522
ADAM
Buy
Dupixent authorization approval rate outweighs Q2 miss, says Canaccord
Regeneron (REGN) partner Sanofi (SNY) reported a "very high" 73%-83% prior authorization approval rate for Dupixent in Q2, which Canaccord analyst John Newman said outweighs the fact that sales for the drug at $30.6M were slightly below the $33M consensus forecast. The analyst, who sees rapid payor acceptance of Dupixent as "much more crucial" than the initial quarterly revenue, keeps a Buy rating and $522 price target on Regeneron shares.

TODAY'S FREE FLY STORIES

PQG

PQ Group

$16.67

-0.2 (-1.19%)

05:16
10/24/17
10/24
05:16
10/24/17
05:16
Initiation
PQ Group initiated  »

PQ Group initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRTO

Criteo

$46.14

0.13 (0.28%)

, AAPL

Apple

$156.17

-0.08 (-0.05%)

05:15
10/24/17
10/24
05:15
10/24/17
05:15
Downgrade
Criteo, Apple rating change  »

Criteo downgraded to…

CRTO

Criteo

$46.14

0.13 (0.28%)

AAPL

Apple

$156.17

-0.08 (-0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

  • 02

    Nov

PQG

PQ Group

$16.67

-0.2 (-1.19%)

05:10
10/24/17
10/24
05:10
10/24/17
05:10
Initiation
PQ Group initiated  »

PQ Group initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TROX

Tronox

$26.58

0.25 (0.95%)

05:08
10/24/17
10/24
05:08
10/24/17
05:08
Initiation
Tronox initiated  »

Tronox initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Nov

PQG

PQ Group

$16.67

-0.2 (-1.19%)

05:06
10/24/17
10/24
05:06
10/24/17
05:06
Initiation
PQ Group initiated  »

PQ Group initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARNC

Arconic

$24.35

-2.82 (-10.38%)

05:04
10/24/17
10/24
05:04
10/24/17
05:04
Recommendations
Arconic analyst commentary  »

Arconic selloff yesterday…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PQG

PQ Group

$16.67

-0.2 (-1.19%)

05:01
10/24/17
10/24
05:01
10/24/17
05:01
Initiation
PQ Group initiated  »

PQ Group initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ON

ON Semiconductor

$20.08

0.01 (0.05%)

04:59
10/24/17
10/24
04:59
10/24/17
04:59
Recommendations
ON Semiconductor analyst commentary  »

ON Semiconductor price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

TECH

Bio-Techne

$123.88

-0.37 (-0.30%)

04:58
10/24/17
10/24
04:58
10/24/17
04:58
Recommendations
Bio-Techne analyst commentary  »

Bio-Techne price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

  • 30

    Nov

ABT

Abbott

$56.08

-0.24 (-0.43%)

, DXCM

Dexcom

$44.77

-0.01 (-0.02%)

04:55
10/24/17
10/24
04:55
10/24/17
04:55
Conference/Events
Leerink medical devices analysts hold an analyst/industry conference call »

Analysts discuss…

ABT

Abbott

$56.08

-0.24 (-0.43%)

DXCM

Dexcom

$44.77

-0.01 (-0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 01

    Nov

  • 06

    Nov

DDAIF

Daimler AG

$80.60

0.03 (0.04%)

04:55
10/24/17
10/24
04:55
10/24/17
04:55
Conference/Events
Daimler AG management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

PAY

Verifone

$19.85

-0.21 (-1.05%)

04:55
10/24/17
10/24
04:55
10/24/17
04:55
Conference/Events
Verifone management to meet with Craig-Hallum »

Meeting to be held in Las…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 14

    Dec

FSBK

First South Bancorp

$18.99

0.33 (1.77%)

, CARO

Carolina Financial

$36.80

0.63 (1.74%)

04:55
10/24/17
10/24
04:55
10/24/17
04:55
Conference/Events
Carolina Financial to host special shareholder meeting »

Special Shareholder…

FSBK

First South Bancorp

$18.99

0.33 (1.77%)

CARO

Carolina Financial

$36.80

0.63 (1.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 26

    Oct

AQXP

Aquinox

$12.47

-0.27 (-2.12%)

04:55
10/24/17
10/24
04:55
10/24/17
04:55
Conference/Events
Aquinox management to meet with Needham »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 25

    Oct

  • 07

    Dec

MRK

Merck

$63.40

-0.48 (-0.75%)

, TKPYY

Takeda Pharmaceutical Co. Ltd.

$28.01

-0.055 (-0.20%)

04:55
10/24/17
10/24
04:55
10/24/17
04:55
Conference/Events
World Congress to hold a summit »

5th Annual Patient…

MRK

Merck

$63.40

-0.48 (-0.75%)

TKPYY

Takeda Pharmaceutical Co. Ltd.

$28.01

-0.055 (-0.20%)

PFE

Pfizer

$36.40

-0.02 (-0.05%)

AGN

Allergan

$187.77

-0.51 (-0.27%)

ONCE

Spark Therapeutics

$83.69

1.82 (2.22%)

PODD

Insulet

$61.02

-0.56 (-0.91%)

ACHN

Achillion

$4.01

-0.14 (-3.37%)

SNY

Sanofi

$49.62

0.11 (0.22%)

ABEO

Abeona Therapeutics

$18.60

-0.4 (-2.11%)

JNJ

Johnson & Johnson

$143.62

1.22 (0.86%)

AZN

AstraZeneca

$34.39

-0.23 (-0.66%)

SHPG

Shire

$144.78

-0.47 (-0.32%)

GSK

GlaxoSmithKline

$40.62

-0.22 (-0.54%)

BMY

Bristol-Myers

$63.75

-0.67 (-1.04%)

SCMP

Sucampo

$10.10

-0.2 (-1.94%)

PCRX

Pacira

$32.95

-0.55 (-1.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 26

    Oct

  • 27

    Oct

  • 27

    Oct

  • 28

    Oct

  • 31

    Oct

  • 01

    Nov

  • 01

    Nov

  • 02

    Nov

  • 06

    Nov

  • 07

    Nov

  • 08

    Nov

  • 09

    Nov

  • 09

    Nov

  • 16

    Nov

  • 30

    Nov

  • 12

    Jan

  • 02

    Feb

  • 05

    Mar

  • 06

    Apr

JPM

JPMorgan

$99.34

-0.17 (-0.17%)

, C

Citi

04:55
10/24/17
10/24
04:55
10/24/17
04:55
Conference/Events
eSHOW to hold a conference »

Money 20/20 is being held…

JPM

JPMorgan

$99.34

-0.17 (-0.17%)

C

Citi

CSCO

Cisco

$34.35

0.1 (0.29%)

BLK

BlackRock

$474.39

-2.23 (-0.47%)

BX

Blackstone

$34.72

0.26 (0.75%)

B

Barnes Group

$70.96

-0.93 (-1.29%)

BCS

Barclays

$10.27

-0.04 (-0.39%)

AMZN

Amazon.com

$966.30

-16.61 (-1.69%)

AKAM

Akamai

$51.46

-0.41 (-0.79%)

CS

Credit Suisse

$16.04

-0.06 (-0.37%)

DFS

Discover

$66.84

0.27 (0.41%)

IBM

IBM

$159.55

-2.52 (-1.55%)

INTC

Intel

$40.83

0.4 (0.99%)

SSNLF

Samsung

PAY

Verifone

$19.85

-0.21 (-1.05%)

MA

MasterCard

$145.56

0.18 (0.12%)

SPLK

Splunk

$64.23

0.14 (0.22%)

V

Visa

$107.53

-0.02 (-0.02%)

WFC

Wells Fargo

$54.91

-0.01 (-0.02%)

GOOG

Alphabet

$968.45

-19.75 (-2.00%)

MSFT

Microsoft

$78.83

0.02 (0.03%)

WMT

Wal-Mart

$88.65

1.21 (1.38%)

GS

Goldman Sachs

$242.13

-2.6 (-1.06%)

FB

Facebook

$171.27

-3.71 (-2.12%)

RY

Royal Bank of Canada

$80.19

-0.07 (-0.09%)

T

AT&T

$35.25

-0.29 (-0.82%)

JEF

Bought by LUK

ADBE

Adobe

$172.16

-3.48 (-1.98%)

BAC

Bank of America

$27.16

-0.01 (-0.04%)

DB

Deutsche Bank

$16.63

-0.35 (-2.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 26

    Oct

  • 26

    Oct

  • 26

    Oct

  • 26

    Oct

  • 26

    Oct

  • 27

    Oct

  • 30

    Oct

  • 30

    Oct

  • 31

    Oct

  • 01

    Nov

  • 01

    Nov

  • 01

    Nov

  • 02

    Nov

  • 05

    Nov

  • 06

    Nov

  • 07

    Nov

  • 07

    Nov

  • 08

    Nov

  • 15

    Nov

  • 15

    Nov

  • 15

    Nov

  • 16

    Nov

  • 17

    Nov

  • 21

    Nov

  • 29

    Nov

  • 29

    Nov

  • 11

    Dec

  • 14

    Dec

  • 15

    Jan

  • 20

    Feb

  • 27

    Feb

  • 18

    Mar

  • 13

    Apr

  • 04

    May

  • 14

    Jul

  • 12

    Oct

ASOMY

ASOS

$73.88

-0.4 (-0.54%)

04:55
10/24/17
10/24
04:55
10/24/17
04:55
Conference/Events
ASOS management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 25

    Oct

  • 26

    Oct

  • 27

    Oct

04:55
10/24/17
10/24
04:55
10/24/17
04:55
General news
Breaking General news story  »

Week of 10/21 Redbook to…

04:55
10/24/17
10/24
04:55
10/24/17
04:55
General news
PMI Composite Flash â€' Level to be reported at 09:45 »

October PMI Composite…

MTNB

Matinas BioPharma

$1.15

-0.08 (-6.50%)

04:55
10/24/17
10/24
04:55
10/24/17
04:55
Conference/Events
Matinas BioPharma management to meet with Oppenheimer »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 25

    Oct

04:55
10/24/17
10/24
04:55
10/24/17
04:55
Conference/Events
The U.S. Commodity Futures Trading Commission holds a symposium »

25th Annual Symposium is…

SNY

Sanofi

$49.62

0.11 (0.22%)

, TKPYY

Takeda Pharmaceutical Co. Ltd.

$28.01

-0.055 (-0.20%)

04:55
10/24/17
10/24
04:55
10/24/17
04:55
Conference/Events
Worldwide Business Research to hold a summit »

BioNetwork Partnering…

SNY

Sanofi

$49.62

0.11 (0.22%)

TKPYY

Takeda Pharmaceutical Co. Ltd.

$28.01

-0.055 (-0.20%)

UNH

UnitedHealth

$207.01

-0.48 (-0.23%)

NVS

Novartis

$85.91

0.17 (0.20%)

HZNP

Horizon Pharma

$13.86

-0.23 (-1.63%)

ABBV

AbbVie

$94.51

-1.59 (-1.65%)

BAYRY

Bayer

$34.51

-0.29 (-0.83%)

MRK

Merck

$63.40

-0.48 (-0.75%)

RDHL

RedHill Biopharma

$9.11

-0.14 (-1.51%)

NBRV

Nabriva Therapeutics

$6.07

-0.26 (-4.11%)

PFE

Pfizer

$36.40

-0.02 (-0.05%)

TEVA

Teva

$14.54

-0.36 (-2.42%)

GILD

Gilead

$80.17

-1.04 (-1.28%)

ALXN

Alexion

$135.20

-3.82 (-2.75%)

GSK

GlaxoSmithKline

$40.62

-0.22 (-0.54%)

REGN

Regeneron

$432.76

-0.22 (-0.05%)

CELG

Celgene

$122.37

1.04 (0.86%)

LLY

Eli Lilly

$87.18

-0.05 (-0.06%)

AMGN

Amgen

$180.53

-2.43 (-1.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 26

    Oct

  • 26

    Oct

  • 26

    Oct

  • 27

    Oct

  • 27

    Oct

  • 28

    Oct

  • 28

    Oct

  • 31

    Oct

  • 02

    Nov

  • 06

    Nov

  • 06

    Nov

  • 07

    Nov

  • 08

    Nov

  • 08

    Nov

  • 09

    Nov

  • 13

    Nov

  • 16

    Nov

  • 16

    Nov

  • 30

    Nov

  • 30

    Nov

  • 02

    Dec

  • 04

    Dec

  • 02

    Feb

  • 03

    Feb

  • 12

    Feb

  • 30

    Apr

  • 17

    May

  • 28

    May

04:55
10/24/17
10/24
04:55
10/24/17
04:55
General news
Breaking General news story  »

4-Week Bill Auction to be…

OMN

Omnova Solutions

$11.40

0.4 (3.64%)

04:55
10/24/17
10/24
04:55
10/24/17
04:55
Conference/Events
Omnova Solutions management to meet with Sidoti »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 25

    Oct

04:55
10/24/17
10/24
04:55
10/24/17
04:55
General news
Richmond Fed Manufacturing Index Level to be reported at 10:00 »

October Richmond Fed…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.